Coudert B, Chaplain G, Milan C, Janoray P
Registre des cancers gynécologiques de Côte d'Or, Dijon, France.
Bull Cancer. 1996 Jan;83(1):54-62.
In the search for changing medical practices, this population-based study dealt with the breakdown of adjuvant systemic breast cancer treatments from 1982 to 1990. The 1,760 women recorded by the cancer registry of the French Côte d'Or region (241,020 women in 1990) during 1982-1990, who were found to have both a non metastatic breast invasive carcinoma and a no perceptible residual disease after locoregional treatment completion were the subjects of this analysis. Forty percent of the patients received adjuvant treatment: 17% only had chemotherapy, 7% had chemotherapy associated with hormonal therapy and 16% only had hormonal therapy. Chemotherapy was the only adjuvant treatment for the patients under 35 years of age. Hormonal therapy was the main treatment for the patients over 74. For patients from 35 to 74 with a non-inflammatory tumour, the determination of adjuvant treatment was multifactorial. For each modality of adjuvant treatment, the logistic regression model provided an assessment of the contribution of each independant variable to the risk of being treated. This method has focused on period effect after adjustment on the tumor and patient characteristics. Adjuvant treatments were more widely used in the late 1980s than in the early 1980s (OR = 1.9; p = 0.006). On the one hand, the use of chemotherapy-hormonal therapy association remained stable and the use of chemotherapy decreased with a boundary significance (OR = 0.6; p = 0.056); on the other hand, the use of hormonal therapy dramatically increased and was 3.5 times as high for the period 1988-1990 as for the period 1982-1984 (OR = 3.5, p < 0.0001). Comprehensive study of survival trends after breast cancer should take into account the adjuvant systemic treatments and the conditions of their indications to separate their potential beneficial effects from the effects of lead time bias. Necessity of treatment indicator quality control was emphasised.
在探寻不断变化的医疗实践过程中,这项基于人群的研究探讨了1982年至1990年辅助性系统性乳腺癌治疗的细分情况。法国科多尔地区癌症登记处记录的1760名女性(1990年该地区有241,020名女性),她们在1982 - 1990年期间被发现患有非转移性乳腺浸润性癌,且在完成局部区域治疗后无明显残留疾病,这些女性是本分析的对象。40%的患者接受了辅助治疗:17%仅接受化疗,7%接受化疗联合激素治疗,16%仅接受激素治疗。化疗是35岁以下患者唯一的辅助治疗方法。激素治疗是74岁以上患者的主要治疗方法。对于35至74岁患有非炎性肿瘤的患者,辅助治疗的确定是多因素的。对于每种辅助治疗方式,逻辑回归模型评估了每个独立变量对接受治疗风险的贡献。该方法在对肿瘤和患者特征进行调整后关注了时期效应。辅助治疗在20世纪80年代后期比80年代早期使用更为广泛(比值比 = 1.9;p = 0.006)。一方面,化疗 - 激素治疗联合使用保持稳定,化疗的使用有所下降且具有临界显著性(比值比 = 0.6;p = 0.056);另一方面,激素治疗的使用大幅增加,1988 - 1990年期间是1982 - 1984年期间的3.5倍(比值比 = 3.5,p < 0.0001)。乳腺癌生存趋势的综合研究应考虑辅助性全身治疗及其适应证情况,以将其潜在有益效果与领先时间偏倚的影响区分开来。强调了治疗指标质量控制的必要性。